<DOC>
	<DOC>NCT00788047</DOC>
	<brief_summary>This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose administration to healthy adult subjects.</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Healthy adult subjects. Extensive or ultrarapid metabolizers of CYP2D6 substrates, predicted by genotype. Existence of significant medical conditions that would impact study results or pose unacceptable risks to study subjects. Pregnant or nursing females or females of childbearing potential who are unwilling or unable to use an acceptable method of contraception. Use of prescription or nonprescription drugs and dietary supplements within 7 days prior to the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>